Headlands Technologies LLC Increases Stock Position in Novartis AG $NVS

Headlands Technologies LLC boosted its holdings in Novartis AG (NYSE:NVS) by 262.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,145 shares of the company’s stock after purchasing an additional 5,172 shares during the quarter. Headlands Technologies LLC’s holdings in Novartis were worth $1,120,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. SOA Wealth Advisors LLC. lifted its stake in shares of Novartis by 4,316.2% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 14,750 shares of the company’s stock worth $2,312,000 after acquiring an additional 14,416 shares during the period. Truist Financial Corp increased its stake in shares of Novartis by 6.6% during the fourth quarter. Truist Financial Corp now owns 887,296 shares of the company’s stock worth $122,332,000 after acquiring an additional 54,682 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Novartis by 40.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock worth $30,715,000 after purchasing an additional 56,424 shares in the last quarter. Brighton Jones LLC lifted its position in Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares during the period. Finally, Mission Wealth Management LP increased its position in Novartis by 85.7% during the 2nd quarter. Mission Wealth Management LP now owns 19,690 shares of the company’s stock worth $3,086,000 after purchasing an additional 9,086 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of NVS opened at $152.22 on Tuesday. Novartis AG has a 12-month low of $121.57 and a 12-month high of $170.46. The stock has a market cap of $290.46 billion, a P/E ratio of 22.96, a PEG ratio of 2.64 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The company has a 50-day moving average of $155.14 and a two-hundred day moving average of $153.72.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. As a group, research analysts predict that Novartis AG will post 8.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on NVS shares. Citigroup reissued a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.